MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Prostate cancer vaccines more effective with hormone therapy

Back to prostate cancer blog Blogs list Cancer blog  


Subscribe To Prostate Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Prostate cancer vaccines more effective with hormone therapy




Among patients with castration-resistant prostate cancer, the addition of hormone treatment following vaccine therapy improved overall survival compared with either therapy alone or when the vaccine followed hormone therapy, as per recent data reported in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.

Philip M. Arlen, M.D., director of the Clinical Research Group for the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, at the National Cancer Institute, said the findings have important implications for guiding therapy decisions for patients with prostate cancer.



Prostate cancer vaccines more effective with hormone therapy

"Vaccines, if and when they are approved, can be safely and effectively combined with other therapies, including hormones," said Arlen. "There appears to be an advantage in overall survival".

Arlen and his colleagues enrolled 42 patients who had castration-resistant prostate cancer. These patients were randomly assigned to receive either a poxvirus-based prostate-specific antigen vaccine or hormone treatment with nilutamide. At progression, patients received the other treatment and continued to receive their original treatment.

For all the patients enrolled in the study, the three-year survival probability was 71 percent and the median overall survival was 4.4 years. Patients randomized to the vaccine had a three-year survival probability of 81 percent and an overall survival of 5.1 years, while patients taking nilutamide had a three-year survival probability of 62 percent and an overall survival of 3.4 years.

Of the 42 patients in the study, 12 patients who were originally assigned to vaccine switched to nilutamide plus vaccine and eight patients who were originally assigned to nilutamide switched to vaccine plus hormone, due to rising levels of prostate-specific antigen with no evidence of metastasis. For patients who received vaccine and then nilutamide, the three-year survival probability was 100 percent with a median overall survival of 6.2 years. For patients who switched to the vaccine after hormone, the three-year survival probability was 75 percent with a median overall survival of 3.7 years.

Arlen said the hormone treatment in combination with the vaccine works in two ways.

"By using hormone treatment in prostate cancer you can help enhance your T-cell response to where the cancer is in the prostate gland, and you are also more likely to achieve a better immune response," said Arlen.

Building on the results of this phase II study, scientists have developed another generation of this vaccine by adding molecules which boost T-cell responses.

Based on the current pace of vaccine research overall, Arlen predicts that men with prostate cancer could potentially see an effective, new therapy vaccine within the next several years.

"Phase II trials such as this one are adding to our knowledge, and other phase III trials are getting ready to publish their data," said Arlen. "If the phase II data hold up in phase III trials, we could see a new therapy vaccine within a few years".


Posted by: Mark    Source




Did you know?
Among patients with castration-resistant prostate cancer, the addition of hormone treatment following vaccine therapy improved overall survival compared with either therapy alone or when the vaccine followed hormone therapy, as per recent data reported in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.

Medicineworld.org: Prostate cancer vaccines more effective with hormone therapy

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.